Final NeuoDeRisk Project Meeting

Thursday, September 15, 2022 – Friday, September 16, 2022, Vienna, Austria (online hybrid access).

Time flies so fast. Time flies especially fast when you work together with such a fantastic team to improve the preclinical prediction of adverse effects of pharmaceuticals on the nervous system. With this meeting, our project comes to an end. One more reason to make this event something special. After a long time with Corona restrictions, we were able to meet again in person. About 25 of our colleagues were able to make their way to Vienna, all others could at least be there with us via a hybrid online meeting. (Unfortunately, they missed the culinary excursion and the typical Austrian dinner in a so-called “Heurigen” and its vineyard.)

On the first day we got a precise overview of our joint achievements of the entire project and each individual work package, including a discussion with the focus on the impact of our deliverables. That same evening, the previously mentioned excursion to a typical Autrian wine tavern (“Heurigen“) also took place. In a relaxed atmosphere, the previous discussions about the great achievements of NeuroDeRisk were continued and, of course, many thanks and praise were exchanged. Naturally accompanied by delicious specialties.

After the delicious conclusion of the first day, the second day begins again full of motivation. The path towards enabling sustainability of the results and the collaboration network were the central topics on this day. With possible options for the future, also the last day of the meeting was a great success.

Finally, we only have one last important point to emphasize: Many thanks to each and every colleague. Working together with such a great team, even in challenging times, has been a pleasure and an honor for all of us. And all of this, of course, always with the focus on our common mission:

To ensure both significant benefits for society by helping patients by delivering safer, better medicines, protecting human volunteers in clinical trials, and finally making the R&D process more efficient by helping industry with top level science to de-risk the discovery of new drugs with high unmet medical need.